Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

TWi Pharma of Taiwan Gains US Approval for Calcium-Channel Blocker

publication date: Apr 7, 2014
TWi Pharma of Taiwan was granted US approval to market a generic version of Procardia XL® (nifedipine) Extended Release Tablets. Procardia XL is member of the calcium-channel blocker class of drugs, administered to treat high blood pressure and chest pain. TWi Pharma makes generics that are difficult to produce or have novel delivery systems, all of which are intended only for the US market. The nifedipine product is the company’s first to be approved. More details....

Stock Symbol: (TWO: 4180)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital